These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30255262)

  • 41. Bullous central serous chorioretinopathy with retinal pigment epithelial macro rip treated with eplerenone monotherapy.
    Naharwal A; Samanta R; Jayaraj S; Agrawal A
    BMJ Case Rep; 2024 Aug; 17(8):. PubMed ID: 39214585
    [No Abstract]   [Full Text] [Related]  

  • 42. Central serous chorioretinopathy in primary hyperaldosteronism.
    van Dijk EH; Nijhoff MF; de Jong EK; Meijer OC; de Vries AP; Boon CJ
    Graefes Arch Clin Exp Ophthalmol; 2016 Oct; 254(10):2033-2042. PubMed ID: 27393297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topical Dexamethasone as an Adjuvant to Mineralocorticoid Receptor Antagonists for the Treatment of Recalcitrant Central Serous Chorioretinopathy.
    Wong A; Zhu D; Li AS; Lee JG; Ferrone PJ
    Ophthalmic Surg Lasers Imaging Retina; 2022 Dec; 53(12):659-665. PubMed ID: 36547963
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy].
    Maier M; Stumpfe S; Feucht N; Strobl P; Rath V; Lohmann CP
    Ophthalmologe; 2014 Feb; 111(2):173-80. PubMed ID: 24510173
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of the mineralocorticoid receptor antagonist treatment for central serous chorioretinopathy: a systematic review and meta-analysis.
    Duan J; Zhang Y; Zhang M
    Eye (Lond); 2021 Apr; 35(4):1102-1110. PubMed ID: 33414535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The relation of the serum aldosterone level and central serous chorioretinopathy - a pilot study.
    Gong Q; Sun XH; Yuan ST; Liu QH
    Eur Rev Med Pharmacol Sci; 2017 Feb; 21(3):446-453. PubMed ID: 28239828
    [TBL] [Abstract][Full Text] [Related]  

  • 47. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive Factors of Response to Mineralocorticoid Receptor Antagonist in Nonresolving Central Serous Chorioretinopathy.
    Călugăru D; Călugăru M
    Am J Ophthalmol; 2019 May; 201():87-88. PubMed ID: 30683307
    [No Abstract]   [Full Text] [Related]  

  • 49. Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends.
    Abdelhakeem E; El-Nabarawi M; Shamma R
    Br J Clin Pharmacol; 2022 Jun; 88(6):2665-2672. PubMed ID: 34983084
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience.
    Petkovsek DS; Cherfan DG; Conti FF; Hom GL; Ehlers JP; Babiuch AS; Rachitskaya AV; Kaiser PK; Schachat AP; Srivastava SK; Sharma S; Singh RP
    Br J Ophthalmol; 2020 Feb; 104(2):182-187. PubMed ID: 31079056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
    Awasthi U; Grover R; Varshney A; Videkar C
    Am J Ophthalmol; 2019 Jul; 203():121. PubMed ID: 31126617
    [No Abstract]   [Full Text] [Related]  

  • 52. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
    Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R
    Am J Ophthalmol; 2019 May; 201():86-87. PubMed ID: 30616898
    [No Abstract]   [Full Text] [Related]  

  • 53. Eplerenone for chronic central serous chorioretinopathy.
    Sacconi R; Borrelli E; Querques G
    Lancet; 2020 Nov; 396(10262):1556. PubMed ID: 33189168
    [No Abstract]   [Full Text] [Related]  

  • 54. Eplerenone for chronic central serous chorioretinopathy.
    Stanescu-Segall D; Touhami S; Bodaghi B; LeHoang P
    Lancet; 2020 Nov; 396(10262):1556-1557. PubMed ID: 33189169
    [No Abstract]   [Full Text] [Related]  

  • 55. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
    Zhao M; Zhang F; Chen Y; Dai H; Qu J; Dong C; Kang X; Liu Y; Yang L; Li Y; Zhou P; Pan CT; Zhang L; Liu P; Zhou H; Jiao X; Xiong Y; Tian R; Lu Y; Yu X; Li X
    JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy.
    Xia Y; Hua R
    Eye (Lond); 2021 Dec; 35(12):3445-3447. PubMed ID: 33257799
    [No Abstract]   [Full Text] [Related]  

  • 57. Infographic: Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months: the VICI study.
    Yusuf IH; Henein C; Sivaprasad S
    Eye (Lond); 2024 Aug; 38(Suppl 2):33-34. PubMed ID: 37085716
    [No Abstract]   [Full Text] [Related]  

  • 58. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Central serous chorioretinopathy: Towards an evidence-based treatment guideline.
    van Rijssen TJ; van Dijk EHC; Yzer S; Ohno-Matsui K; Keunen JEE; Schlingemann RO; Sivaprasad S; Querques G; Downes SM; Fauser S; Hoyng CB; Piccolino FC; Chhablani JK; Lai TYY; Lotery AJ; Larsen M; Holz FG; Freund KB; Yannuzzi LA; Boon CJF
    Prog Retin Eye Res; 2019 Nov; 73():100770. PubMed ID: 31319157
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reply to: 'Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy'.
    Lotery A; Sivaprasad S; O'Connell A; Reeves B
    Eye (Lond); 2021 Dec; 35(12):3448. PubMed ID: 34089001
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.